---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-108839"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:38:24.629365+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ArriVent reports Q3 net loss $130.8M; cash $305.4M funds into mid-2027

## Summary
- Net loss $130.8M for nine months ended Sep 30, 2025, up from $59.9M in 2024, driven by R&D spend including $40M upfront for ARR-217.
- Cash and investments $305.4M as of Sep 30, 2025; expected to fund operations into mid-2027.
- R&D expense $121.2M (incl. $40M upfront for ARR-217 license) vs $58.8M prior year; G&A $17.5M vs $11.8M.
- Appointed Brent S. Rice as Chief Commercial Officer; Phase 1b firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC.
- Phase 3 ALPACCA trial for PACC mutant NSCLC first patient enrollment expected Q4 2025; topline FURVENT Phase 3 data in exon 20 insertion NSCLC projected early 2026.

## SEC filing metadata
- accession: 0001104659-25-108839
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/0001104659-25-108839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/avbp-20251110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-108839
- JSON: https://secwatch.observer/filing/0001104659-25-108839.json
- Plain text: https://secwatch.observer/filing/0001104659-25-108839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.